Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.

PloS one - 1 Jan 2012

Scherrer Alexandra U, Böni Jürg, Yerly Sabine, Klimkait Thomas, Aubert Vincent, Furrer Hansjakob, Calmy Alexandra, Cavassini Matthias, Elzi Luigia, Vernazza Pietro L, Bernasconi Enos, Ledergerber Bruno, Günthard Huldrych F

Abstract excerpt

BACKGROUND: The accumulation of mutations after long-lasting exposure to a failing combination antiretroviral therapy (cART) is problematic and severely reduces the options for further successful treatments. METHODS: We studied patients from the Swiss HIV Cohort Study who failed cART with nucleoside reverse transcriptase inhibitors (NRTIs) and either a ritonavir-boosted PI (PI/r) or a non-nucleoside reverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Infections

Share to Protease Inhibitors

Share to Reverse Transcriptase Inhibitors

Share to Treatment Failure

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 23189194
DOI: 10.1371/journal.pone.0050307
PMCID: PMC3506586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.PMID 23189194Read ↗

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.Semantic proximity Read ↗

Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.Semantic proximity Read ↗

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.Semantic proximity Read ↗

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.Semantic proximity Read ↗

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.Semantic proximity Read ↗

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.Semantic proximity Read ↗

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.Semantic proximity Read ↗

Clearance of archived integrase strand transfer inhibitors resistance mutations in people with virologically suppressed HIV infectionSemantic proximity Read ↗

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.Semantic proximity Read ↗

Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.Semantic proximity Read ↗

The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.Semantic proximity Read ↗

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.